Literature DB >> 6464707

Antigenicity and protein content of perilymph in acoustic neuroma patients.

N Rasmussen, K Bendtzen, J Thomsen, M Tos.   

Abstract

11 acoustic neuroma patients, exhibiting cell-mediated immunity in vitro against acoustic neuroma extract, were tested for cell-mediated immunity in vitro against perilymph samples from other acoustic neuroma patients. 14 of 21 perilymph samples were antigenic. None of three healthy persons reacted against antigenic perilymph samples. The perilymph antigenicity was reproducible and negatively correlated to the perilymph sample volume. Differences in sample volume could not be ascribed to admixture of endolymph, cerebrospinal fluid, plasma or blood. The perilymph protein concentration varied from 31 to 54 g/l. Gel electrophoresis of perilymph proteins revealed less staining in the alpha-region compared to plasma proteins and a distinct band in the pre-gamma region absent in plasma. Tau-transferrin was not detected in any of 13 samples. The findings support that the cell-mediated immune response against acoustic neuroma extract may be mediated through release of antigen(s) to the perilymph.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6464707     DOI: 10.3109/00016488409132928

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  9 in total

1.  Increased signal intensity of the cochlea on pre- and post-contrast enhanced 3D-FLAIR in patients with vestibular schwannoma.

Authors:  Masahiro Yamazaki; Shinji Naganawa; Hisashi Kawai; Takashi Nihashi; Hiroshi Fukatsu; Tsutomu Nakashima
Journal:  Neuroradiology       Date:  2009-12       Impact factor: 2.804

2.  Signal intensity change of the labyrinth in patients with surgically confirmed or radiologically diagnosed vestibular schwannoma on isotropic 3D fluid-attenuated inversion recovery MR imaging at 3 T.

Authors:  In Ho Lee; Hyung-Jin Kim; Won Ho Chung; Eunhee Kim; Jung Won Moon; Sung Tae Kim; Keon Ha Kim; Pyoung Jeon; Hong Sik Byun
Journal:  Eur Radiol       Date:  2009-11-07       Impact factor: 5.315

3.  Endolympathic hydrops in patients with vestibular schwannoma: visualization by non-contrast-enhanced 3D FLAIR.

Authors:  Shinji Naganawa; Hisashi Kawai; Michihiko Sone; Tsutomu Nakashima; Mitsuru Ikeda
Journal:  Neuroradiology       Date:  2011-01-11       Impact factor: 2.804

4.  Radiosurgery of vestibular schwannoma: prognostic factors for hearing outcome using 3D-constructive interference in steady state (3D-CISS).

Authors:  Franca Wagner; Matteo Gandalini; Arsany Hakim; Ekin Ermis; Dominic Leiser; Martin Zbinden; Lukas Anschuetz; Andreas Raabe; Marco Caversaccio; Roland Wiest; Evelyn Herrmann
Journal:  Strahlenther Onkol       Date:  2018-09-10       Impact factor: 3.621

5.  Decreased vestibular signal intensity on 3D-FIESTA in vestibular schwannomas differentiating from meningiomas.

Authors:  Kazuhiro Ishikawa; Jun Haneda; Kouichirou Okamoto
Journal:  Neuroradiology       Date:  2012-10-16       Impact factor: 2.804

6.  Clinical significance of an increased cochlear 3D fluid-attenuated inversion recovery signal intensity on an MR imaging examination in patients with acoustic neuroma.

Authors:  D Y Kim; J H Lee; M J Goh; Y S Sung; Y J Choi; R G Yoon; S H Cho; J H Ahn; H J Park; J H Baek
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

7.  Increased cochlear fluid-attenuated inversion recovery signal in patients with vestibular schwannoma.

Authors:  R A Bhadelia; K L Tedesco; S Hwang; S H Erbay; P H Lee; W Shao; C Heilman
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-31       Impact factor: 3.825

8.  Audiovestibular Function Deficits in Vestibular Schwannoma.

Authors:  Constantin von Kirschbaum; Robert Gürkov
Journal:  Biomed Res Int       Date:  2016-09-22       Impact factor: 3.411

Review 9.  Biomarkers in Vestibular Schwannoma-Associated Hearing Loss.

Authors:  Luis Lassaletta; Miryam Calvino; Jose Manuel Morales-Puebla; Pablo Lapunzina; Lourdes Rodriguez-de la Rosa; Isabel Varela-Nieto; Victor Martinez-Glez
Journal:  Front Neurol       Date:  2019-09-18       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.